新城疫病毒载体传染性喉气管炎疫苗在存在母源抗体时保护商品肉鸡
本研究评估新城疫病毒(NDV)载体表达传染性喉气管炎病毒(ILTV)糖蛋白B和D的重组疫苗在具有母源抗体的商品肉鸡中的保护效果。雏鸡在1日龄或10日龄或两日龄均接种rLS/ILTV-gB或rLS/ILTV-gD,并设商品ILT疫苗组和假接种组,21日龄用强毒ILTV攻毒。结果表明母源抗体未显著干扰疫苗诱导的保护性免疫,rLS/ILTV-gD保护优于rLS/ILTV-gB,且10日龄加强免疫未改善保护。
要点
- NDV载体ILTV gB和gD疫苗在母源抗体存在下仍能诱导显著临床保护。
- rLS/ILTV-gD的保护效果优于rLS/ILTV-gB,并减少气管和眼部ILTV排毒约3 log10 TCID50。
- 10日龄加强免疫未改善保护效果。
核心结论
- 对NDV和ILTV的母源抗体未显著干扰NDV LaSota株载体ILTV gB和gD候选疫苗诱导针对传染性喉气管炎的保护性免疫。
研究设计与样本
- 研究将具有NDV母源抗体平均血凝抑制(HI)效价6.4(log2)且孵化时ILTV中和抗体可检测的肉鸡,在1日龄或10日龄或两日龄均接种rLS/ILTV-gB或rLS/ILTV-gD。
- 研究同时设商品ILT疫苗(FP-LT和CEO)组和假接种组,所有接种鸡在21日龄用强毒ILTV株攻毒。
主要发现
- 攻毒时未接种鸡的NDV HI效价降至2.6(log2),而NDV载体疫苗组HI效价升至3.5-6.3(log2)。
- 标准剂量下两种候选疫苗均提供显著临床保护,但rLS/ILTV-gD诱导的保护优于rLS/ILTV-gB。
- 重组rLS/ILTV-gD使气管和眼部组织的ILTV排毒减少约3 log10 TCID50。
- 10日龄加强免疫后保护效果未见改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Newcastle disease virus (NDV) recombinants expressing the infectious laryngotracheitis virus (ILTV) glycoproteins B and D have previously been demonstrated to confer complete clinical protection against virulent ILTV and NDV challenges in naive chickens. We extended this study to assess whether maternally derived antibody (MDA) against NDV and ILTV would interfere with protection in vaccinated broiler chickens. Chickens with a mean NDV MDA hemagglutination inhibition (HI) titer of 6.4 (log2) and detectable ILTV neutralization (VN) antibodies at hatch were vaccinated with rLS/ILTV-gB or rLS/ILTV-gD at 1 or 10day of age (DOA) or on both days. Groups of birds vaccinated with the commercial ILT vaccines (FP-LT and CEO) or sham inoculated were also included in this study. All vaccinated birds were challenged with virulent ILTV strain at 21 DOA. By that time, NDV HI titers declined to 2.6 (log2) in unvaccinated birds, whereas the HI titers in NDV vectored vaccine groups increased to 3.5-6.3 (log2). At standard dosages, both vaccine candidates conferred significant clinical protection; however, the protection elicited by the rLS/ILTV-gD was superior to that of rLS/ILTV-gB. Recombinant rLS/ILTV-gD reduced ILTV shedding from tracheal and ocular tissues by approximately 3 log10 TCID50. Notably, there was no improvement in protection after booster vaccination at 10 DOA. Overall results indicate that the presence of maternal antibodies to NDV and ILTV did not significantly interfere with the ability of the NDV LaSota strain-vectored ILTV gB and gD vaccine candidates to elicit protective immunity against infectious laryngotracheitis.
引用
- Yu Q, Spatz S, Li Y, et al. Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies. Vaccine. 2017. PMID: 28052812. doi:10.1016/j.vaccine.2016.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。